Decentralizing Biopharmaceutical Innovation: A Community-Governed Model for Drug Development and Equitable Drug Pricing

Abstract

The rising cost of drug development and the monopolization of pharmaceutical intellectual property have contributed to opaque pricing and limited access to life-saving therapeutics. This paper introduces VitaDAO, a novel decentralized autonomous organization (DAO) designed to address critical inefficiencies in early-stage biopharmaceutical research and drug pricing. By leveraging blockchain technology, token-based governance, and IP tokenization through NFTs, VitaDAO democratizes the funding and ownership of longevity-focused therapeutics. The model aligns incentives across patients, researchers, and investors, fostering open science and equitable commercialization pathways. It proposes a new framework for holding, funding, and managing pharmaceutical IP and research data that seeks to reduce drug prices, enhance transparency, and accelerate access to innovative therapies. This work sits at the intersection of health economics, pharmaceutical RD, and decentralized governance, offering a disruptive alternative to traditional pharma business models.